284 related articles for article (PubMed ID: 15665857)
1. The histamine H3 receptor: from gene cloning to H3 receptor drugs.
Leurs R; Bakker RA; Timmerman H; de Esch IJ
Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857
[TBL] [Abstract][Full Text] [Related]
2. Molecular aspects of the histamine H3 receptor.
Bongers G; Bakker RA; Leurs R
Biochem Pharmacol; 2007 Apr; 73(8):1195-204. PubMed ID: 17276412
[TBL] [Abstract][Full Text] [Related]
3. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Esbenshade TA; Fox GB; Cowart MD
Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
[TBL] [Abstract][Full Text] [Related]
4. [The histamine H(3) receptor: a target for new drugs].
Arrang JM
Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
[TBL] [Abstract][Full Text] [Related]
5. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
6. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of histamine H3 receptor antagonists in dementias.
Chazot PL
Drug News Perspect; 2010 Mar; 23(2):99-103. PubMed ID: 20369074
[TBL] [Abstract][Full Text] [Related]
8. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
Vohora D
IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
[TBL] [Abstract][Full Text] [Related]
9. H3 receptor antagonists/inverse agonists as anti-obesity agents.
Hancock AA
Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
[TBL] [Abstract][Full Text] [Related]
10. Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS?
Chazot PL; Hann V
Curr Opin Investig Drugs; 2001 Oct; 2(10):1428-31. PubMed ID: 11890359
[No Abstract] [Full Text] [Related]
11. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
[TBL] [Abstract][Full Text] [Related]
12. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
Witkin JM; Nelson DL
Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
[TBL] [Abstract][Full Text] [Related]
13. Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.
Pan JB; Yao BB; Miller TR; Kroeger PE; Bennani YL; Komater VA; Esbenshade TA; Hancock AA; Decker MW; Fox GB
Life Sci; 2006 Aug; 79(14):1366-79. PubMed ID: 16730751
[TBL] [Abstract][Full Text] [Related]
14. Histamine H3 receptor as a drug discovery target.
Berlin M; Boyce CW; Ruiz Mde L
J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
[No Abstract] [Full Text] [Related]
15. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.
Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H
J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422
[TBL] [Abstract][Full Text] [Related]
17. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
Ito S; Yoshimoto R; Miyamoto Y; Mitobe Y; Nakamura T; Ishihara A; MacNeil DJ; Kanatani A; Tokita S
Eur J Pharmacol; 2006 Jan; 529(1-3):40-6. PubMed ID: 16316645
[TBL] [Abstract][Full Text] [Related]
18. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
19. [The histaminergic system: a target for innovative treatments of cognitive deficits].
Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
[TBL] [Abstract][Full Text] [Related]
20. Recent medicinal chemistry of the histamine H3 receptor.
Letavic MA; Barbier AJ; Dvorak CA; Carruthers NI
Prog Med Chem; 2006; 44():181-206. PubMed ID: 16697898
[No Abstract] [Full Text] [Related]
[Next] [New Search]
